sefulness of belimumab in adult patients with systemic lupus erythematosus evaluated using single indexes: a meta-analysis and systematic review.

Not Applicable

• Conditions: Systemic Lupus Erythematosus

• Registration Number: JPRN-UMIN000052846
• Lead Sponsor: Meiji Pharmaceutical University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2023-11-20
• Last Update Posted: 22 January 2024
• Study Completion: 2024-01-31

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 8197

Inclusion Criteria

Not provided

Exclusion Criteria

We exclude clinical studies that meet the following exclusion criteria: 1) not interventional studies; 2) non-original research articles such as reviews, case reports, letters, and research protocols; 3) no data description; 4) studies in children; 5) patients with lupus nephritis; 6) single-dose studies.

Study & Design

• Study Type: Others,meta-analysis etc
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
umber of patients who achieved a >= 4-point reduction in SLE Disease Activity Index (SLEDAI) score.

Secondary Outcome Measures

Name	Time	Method
umber of patients whose BILAG score did not worsening, Number of patients whose PGA score did not worsening, Short Form 36 health survey (SF-36) score, and SLICC/ACR damage index (SDI), Number of adverse events.